Similarly, B7 ligands B7-1 (CD80) and B7-2 (CD86) on tumor cells engage CTLA-4 on activated CD8+ T cells, outcompeting CD28 and thereby blocking co-stimulatory signals required for T cell activation, leading to CD8+ T cell anergy. Here, CD86 is linked to neoplasm.